Aminophylline
- Atc Codes:R03DA05
- CAS Codes:317-34-0#5897-66-5
- PHARMGKB ID:317-34-0#5897-66-5
Table of contents
- Brand Names
- Drug Combinations
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Unlabeled Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Caution and personalized dose adjustment in patients with the following genotypes
- Other genes that may be involved
- Substrate of
- Drug Interactions
- Nutrition/Nutraceutical Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Bulgaria: Novphyllin, Sophafyllin; Cyprus: Phyllocontin Continus; Finland: Aminocont; France: Aminophylline; Germany: Aminophyllin; Greece: Aminophylline; Hungary: Aminophyllinum, Diaphyllin; Ireland: Aminophylline, Phyllocontin Continus; Italy: Aminofil, Aminomal, Tefamin; Latvia: Eifilīns, Sophafyllin; Luxembourg: Aminoslow; Malta: Aminophylline; Poland: Aminofilina, Aminophyllinum; Portugal: Aminofilina, Filotempo; Romania: Aminofilin, Aminofilina, Miofilin; Slovakia: Syntophyllin; Slovenia: Aminophyllinum; UK: Aminophylline, Phyllocontin Continus.
North America
Canada: Aminophylline, Phyllocontin; USA: Aminophylline.
Latin America
Argentina: Aminofilina, Fadafilina, Larjanfilina; Brazil: Aminofilina, Aminoima, Aminoliv, Asmapen, Asmodrin, Asmoquinol, Minoton, Pulmodilat; Mexico: Aminofilina, Amofilin, Drafilyn.
Asia
Japan: Albina, Aminophylline, Anephyllin, Apnission, Kyophyllin, Microfillin, Neophyllin, Nichfylin, Nichifylin, Theocardin.
Drug combinations
Bronchodilators and Theophylline
Chemistry
Aminophylline: C~16~H~24~N~10~O~4~. Mw: 420.43. (1) 1H-Purine-2,6-dione, 3,7-dihydro-1,3-dimethyl-, compd. with 1,2-ethanediamine (2:1); (2) Theophylline compound with ethylenediamine (2:1). CAS-317-34-0; CAS-5897-66-5 (dihydrate).
Pharmacologic Category
Bronchodilators; Xanthine Derivatives. (ATC-Code: R03DA05).
Mechanism of action
Causes bronchodilatation, diuresis, CNS and cardiac stimulation and gastric acid secretion by blocking phosphodiesterase (increases tissue concentrations of cAMP). Promotes catecholamine stimulation of lipolysis, glycogenolysis, and gluconeogenesis and induces release of epinephrine from adrenal medulla cells.
Therapeutic use
Bronchodilator in reversible airway obstruction due to asthma or chronic obstructive pulmonary disease. Increases diaphragmatic contractility.
Pregnancy and lactiation implications
Adverse effects may occur in the newborn. Theophylline metabolism may change during pregnancy. Irritability may be observed in the nursing infant.
Unlabeled use
Reversal of adenosine-, dipyridamole- or regadenoson-induced adverse reactions (e.g. angina, hypotension) during nuclear cardiac stress testing.
Contraindications
Hypersensitivity to theophylline, ethylenediamine or any component of the formulation.
Warnings and precautions
Theophylline toxicity (≥ 20 μg/mL) might be developed. Use with caution in cardiovascular disease (hypertension or cardiac arrhythmias, excluding bradyarrhythmias), hyperthyroidism, peptic ulcer disease or in seizure disorder.